Research programme: ALK expression companion diagnostic - Insight Genetics/QIAGEN

Drug Profile

Research programme: ALK expression companion diagnostic - Insight Genetics/QIAGEN

Alternative Names: Anaplastic lymphoma kinase expression companion diagnostic - Insight Genetics/QIAGEN; Insight ALK Screen

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Insight Genetics
  • Developer Insight Genetics; QIAGEN
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Lung cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Lung-cancer(Diagnosis) in Unknown
  • 12 Nov 2012 Insight Genetics receives SBIR grant from National Cancer Institute for ALK expression companion diagnostic development in Lung cancer
  • 31 Jan 2012 Early research in Lung cancer (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top